As of November 6, 2026, Research Alliance Corp III has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 21, 2026 (Form 8-K, May 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Research Alliance Corp III? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Research Alliance Corp III reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-21. Every row below is cited to the filing it comes from, and this page adds each new change as Research Alliance Corp III files it.
Also on the record for Research Alliance Corp III
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | — | 5%+ stakes | Source |
| October 7, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 14.1% of the class | 5%+ stakes | Source |
| September 11, 2026 | Stake report, Schedule 13G, by Great Point Partners, LLC | 6.49% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 8.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by BALYASNY ASSET MANAGEMENT L.P. | 6.43% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by TCG Crossover GP III, LLC | 6.4% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Spruce Street Capital LP | 6.4% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 6.5% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13D/A, by Research Alliance Holdings III LLC | 16.9% of the class | 5%+ stakes | Source |
| May 29, 2026 | Stake report, Schedule 13D, by Research Alliance Holdings III LLC | 14.7% of the class | 5%+ stakes | Source |
| May 29, 2026 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 6.4% of the class | 5%+ stakes | Source |
| May 29, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 5.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Research Alliance Corp III now and the warning signs.
Free to see. No signup.
Keep reading
More on Research Alliance Corp III and the records around it.
Research Alliance Corp III elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Spruce Street Capital LP also filed stake reports on 1 other company: RELMADA THERAPEUTICS, INC. (Feb 2026)
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Entera Bio Ltd. (Aug 2026), Editas Medicine, Inc. (Jun 2026), InflaRx N.V. (May 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), JATT III Acquisition Corp (Sep 2026), AMANAT ACQUISITION CORP (Aug 2026)
Watch Research Alliance Corp III
Get an email when Research Alliance Corp III files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Research Alliance Corp III?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Research Alliance Corp III: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Research Alliance Corp III covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-21 | Reported | not named in the filing | 8-K, 2026-05-21 |
New leaders reset buying decisions — get the Full Report on Research Alliance Corp III: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Research Alliance Corp III, with the record behind each one.
Find candidates like senior executive at Research Alliance Corp IIIEvery change, in the filing's words
Reported
On May 19, 2026, and in connection with the IPO, Michael F. MacLean and Timothy J. Miller were appointed to the board of directors of the Company (the "Board").
- Effective May 19, 2026, (i) each of Mr. MacLean and Mr. Miller was appointed to the Board's Audit Committee, with Mr. MacLean serving as its chair; (ii) each of Matthew Hammond, Mr. MacLean, and Mr. Miller was appointed to the Board's Nominating Committee, with Mr. Miller serving as its chair; and (iii) each of Mr. MacLean and Mr. Miller was appointed to the Board's Compensation Committee, with Mr. Miller serving as its chair.
- In March 2026, the Sponsor transferred 30,000 Class B ordinary shares of the Company, par value $0.0001 per share ("Class B ordinary shares"), to each of Mr. MacLean and Mr. Miller as compensation for his service as a director of the Company.
- In May 2026, in connection with a share capitalization effected to maintain the initial shareholders' ownership at 15% of the issued and outstanding ordinary shares (excluding the Private Placement Shares) upon consummation of the IPO, an additional 9,130 Class B ordinary shares were issued to each of Mr. MacLean and Mr. Miller, resulting in each of Mr. MacLean and Mr. Miller holding 39,130 Class B ordinary shares.
Tools for this story
Each opens in a new tab, filled in for Research Alliance Corp III. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.